{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:59:11Z","timestamp":1790643551232,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["International Orthopaedics (SICOT)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00264-026-07024-6","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:21:37Z","timestamp":1788834097000},"page":"2477-2485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4330-8393","authenticated-orcid":false,"given":"Jacob D.","family":"Kodra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0859-7980","authenticated-orcid":false,"given":"Austen","family":"Schweinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9062-7619","authenticated-orcid":false,"given":"Abdullah A.","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-714X","authenticated-orcid":false,"given":"Logan M.","family":"Andryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-6082","authenticated-orcid":false,"given":"Michael M.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-789X","authenticated-orcid":false,"given":"David M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"7024_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR (2023) Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch 482:163\u2013177","journal-title":"Virchows Arch"},{"key":"7024_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397:410\u2013427","journal-title":"Lancet"},{"key":"7024_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5435\/00124635-201107000-00004","volume":"19","author":"TJ Scharschmidt","year":"2011","unstructured":"Scharschmidt TJ, Lindsey JD, Becker PS et al (2011) Multiple myeloma: diagnosis and orthopaedic implications. J Am Acad Orthop Surg 19:410\u2013419","journal-title":"J Am Acad Orthop Surg"},{"key":"7024_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Gupta VA, Vertino PM et al (2019) Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol 10:1121","journal-title":"Front Immunol"},{"key":"7024_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","volume":"28","author":"RA Kyle","year":"2014","unstructured":"Kyle RA, San-Miguel JF, Mateos MV et al (2014) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 28:775\u2013790","journal-title":"Hematol Oncol Clin North Am"},{"key":"7024_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","volume":"36","author":"N Veronese","year":"2018","unstructured":"Veronese N, Luchini C, Solmi M et al (2018) Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis. J Bone Miner Metab 36:128\u2013132","journal-title":"J Bone Miner Metab"},{"key":"7024_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ejh.13633","volume":"107","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Aspelund T, Thorsteinsd\u00f3ttir S et al (2021) Untangling fracture risk in monoclonal gammopathy of undetermined significance: a population-based cohort study. Eur J Haematol 107:137\u2013144","journal-title":"Eur J Haematol"},{"key":"7024_CR8","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","volume":"116","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM et al (2010) Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 116:2651\u20132655","journal-title":"Blood"},{"key":"7024_CR9","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/jbmr.2387","volume":"29","author":"MT Drake","year":"2014","unstructured":"Drake MT (2014) Unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance. J Bone Miner Res 29:2529\u20132533","journal-title":"J Bone Miner Res"},{"key":"7024_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M et al (2018) Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J 8:7","journal-title":"Blood Cancer J"},{"key":"7024_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126208","author":"SKR Mukkamalla","year":"2021","unstructured":"Mukkamalla SKR, Malipeddi D (2021) Myeloma bone disease: a comprehensive review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22126208","journal-title":"Int J Mol Sci"},{"key":"7024_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063112","author":"YC Gau","year":"2022","unstructured":"Gau YC, Yeh TJ, Hsu CM et al (2022) Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23063112","journal-title":"Int J Mol Sci"},{"key":"7024_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16:437\u2013447","journal-title":"Nat Rev Endocrinol"},{"key":"7024_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jbmr.2415","volume":"30","author":"JM Quach","year":"2015","unstructured":"Quach JM, Askmyr M, Jovic T et al (2015) Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J Bone Miner Res 30:886\u2013897","journal-title":"J Bone Miner Res"},{"key":"7024_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.009","author":"A Feng","year":"2026","unstructured":"Feng A, Wu J, Choi T et al (2026) Musculoskeletal adverse events following BCMA CAR-T cell therapy in multiple myeloma: clinical characteristics and immune correlates. Transplant Cell Ther. https:\/\/doi.org\/10.1016\/j.jtct.2026.02.009","journal-title":"Transplant Cell Ther"},{"key":"7024_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A et al (2021) Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). https:\/\/doi.org\/10.3390\/medsci9010003","journal-title":"Med Sci (Basel)"},{"key":"7024_CR17","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/ijc.33135","volume":"147","author":"Y Usui","year":"2020","unstructured":"Usui Y, Ito H, Koyanagi Y et al (2020) Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study. Int J Cancer 147:3102\u20133109","journal-title":"Int J Cancer"},{"key":"7024_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071929","author":"A Chacon","year":"2023","unstructured":"Chacon A, Leleu X, Bobin A (2023) 30 years of improved survival in non-transplant-eligible newly diagnosed multiple myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15071929","journal-title":"Cancers (Basel)"},{"key":"7024_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV et al (2022) Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia 36:801\u2013808","journal-title":"Leukemia"},{"key":"7024_CR20","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.arth.2023.05.019","volume":"38","author":"MS Salimy","year":"2023","unstructured":"Salimy MS, Blackburn AZ, Alpaugh K et al (2023) Postoperative outcomes in total hip and total knee arthroplasty for patients who have multiple myeloma. J Arthroplasty 38:2269\u20132274","journal-title":"J Arthroplasty"},{"key":"7024_CR21","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.arth.2012.03.036","volume":"27","author":"R Thein","year":"2012","unstructured":"Thein R, Herman A, Chechik A et al (2012) Uncemented arthroplasty for metastatic disease of the hip: preliminary clinical experience. J Arthroplasty 27:1658\u20131662","journal-title":"J Arthroplasty"},{"key":"7024_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5435\/00124635-200001000-00006","volume":"8","author":"KC Swanson","year":"2000","unstructured":"Swanson KC, Pritchard DJ, Sim FH (2000) Surgical treatment of metastatic disease of the femur. J Am Acad Orthop Surg 8:56\u201365","journal-title":"J Am Acad Orthop Surg"},{"key":"7024_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.arth.2016.01.029","volume":"31","author":"ME Menendez","year":"2016","unstructured":"Menendez ME, Park KJ, Barnes CL (2016) Early postoperative outcomes after total joint arthroplasty in patients with multiple myeloma. J Arthroplasty 31:1645\u20131648","journal-title":"J Arthroplasty"},{"key":"7024_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"LJ Melton 3rd","year":"2005","unstructured":"Melton LJ 3rd, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20:487\u2013493","journal-title":"J Bone Miner Res"},{"key":"7024_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1302\/0301-620X.104B2.BJJ-2021-0890.R1","volume":"104-b","author":"B Stone","year":"2022","unstructured":"Stone B, Nugent M, Young SW et al (2022) The lifetime risk of revision following total knee arthroplasty: a New Zealand Joint Registry study. Bone Joint J 104-b:235\u2013241","journal-title":"Bone Joint J"},{"key":"7024_CR26","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1007\/s11999-010-1399-0","volume":"468","author":"KL Ong","year":"2010","unstructured":"Ong KL, Lau E, Suggs J et al (2010) Risk of subsequent revision after primary and revision total joint arthroplasty. Clin Orthop Relat Res 468:3070\u20133076","journal-title":"Clin Orthop Relat Res"},{"key":"7024_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1302\/0301-620X.103B3.BJJ-2020-0562.R2","volume":"103-b","author":"M Nugent","year":"2021","unstructured":"Nugent M, Young SW, Frampton CM et al (2021) The lifetime risk of revision following total hip arthroplasty. Bone Joint J 103-b:479\u2013485","journal-title":"Bone Joint J"},{"key":"7024_CR28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.arth.2015.09.033","volume":"31","author":"DD Bohl","year":"2016","unstructured":"Bohl DD, Samuel AM, Basques BA et al (2016) How much do adverse event rates differ between primary and revision total joint arthroplasty? J Arthroplasty 31:596\u2013602","journal-title":"J Arthroplasty"},{"key":"7024_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0037-1603335","volume":"31","author":"JM Newman","year":"2018","unstructured":"Newman JM, Wagner TC, Naziri Q et al (2018) Hematologic malignancies are associated with adverse perioperative outcomes following total knee arthroplasty. J Knee Surg 31:291\u2013301","journal-title":"J Knee Surg"},{"key":"7024_CR30","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.arth.2017.03.002","volume":"32","author":"JM Newman","year":"2017","unstructured":"Newman JM, George J, North WT et al (2017) Hematologic malignancies are associated with adverse perioperative outcomes after total hip arthroplasty. J Arthroplasty 32:2436-2443.e2431","journal-title":"J Arthroplasty"},{"key":"7024_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.sart.2026.151561","volume":"36","author":"JD Kodra","year":"2026","unstructured":"Kodra JD, Choudhury A, Hanley JM et al (2026) Monoclonal gammopathy of undetermined significance is associated with similar two-year revision rates but increased hospital readmission after total shoulder arthroplasty. Semin Arthroplasty JSES 36:151561","journal-title":"Semin Arthroplasty JSES"},{"key":"7024_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2013-05-505776","volume":"123","author":"JN Farr","year":"2014","unstructured":"Farr JN, Zhang W, Kumar SK et al (2014) Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood 123:647\u2013649","journal-title":"Blood"},{"key":"7024_CR33","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","volume":"118","author":"AC Ng","year":"2011","unstructured":"Ng AC, Khosla S, Charatcharoenwitthaya N et al (2011) Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS. Blood 118:6529\u20136534","journal-title":"Blood"},{"key":"7024_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00774-020-01084-3","volume":"38","author":"G Orduna","year":"2020","unstructured":"Orduna G, Mellibovsky L, Abella E et al (2020) Bone tissue quality in patients with monoclonal gammopathy of uncertain significance. J Bone Miner Metab 38:563\u2013569","journal-title":"J Bone Miner Metab"},{"key":"7024_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2011.054015","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM et al (2012) Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica 97:854\u2013858","journal-title":"Haematologica"},{"key":"7024_CR36","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9:e143\u2013e161","journal-title":"Lancet Haematol"},{"key":"7024_CR37","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.injury.2021.04.062","volume":"52","author":"F Saglam","year":"2021","unstructured":"Saglam F, Baysal \u00d6, Sofulu \u00d6 et al (2021) The impact of pathological fractures on surgery, morbidity, functional and oncological outcomes in patients with primary bone sarcomas. Injury 52:1740\u20131747","journal-title":"Injury"},{"key":"7024_CR38","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.5435\/JAAOS-D-23-00297","volume":"32","author":"A Vankara","year":"2024","unstructured":"Vankara A, Leland CR, Maxson R et al (2024) Predicting risk of 30-day postoperative morbidity using the pathologic fracture mortality index. J Am Acad Orthop Surg 32:e146\u2013e155","journal-title":"J Am Acad Orthop Surg"},{"key":"7024_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3928\/01477447-20170117-03","volume":"40","author":"FC Lovecchio","year":"2017","unstructured":"Lovecchio FC, Manalo JP, Demzik A et al (2017) Avascular necrosis is associated with increased transfusions and readmission following primary total hip arthroplasty. Orthopedics 40:171\u2013176","journal-title":"Orthopedics"},{"key":"7024_CR40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327:464\u2013477","journal-title":"JAMA"}],"container-title":["International Orthopaedics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00264-026-07024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00264-026-07024-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00264-026-07024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:09:56Z","timestamp":1790640596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00264-026-07024-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7024"],"URL":"https:\/\/doi.org\/10.1007\/s00264-026-07024-6","relation":{},"ISSN":["0341-2695","1432-5195"],"issn-type":[{"value":"0341-2695","type":"print"},{"value":"1432-5195","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"8 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study involving human participants was approved by the Medical College of Wisconsin Institutional Review Board. The requirement for informed consent was waived because of the retrospective nature of the study. All procedures were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}